Lantern Pharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates As we move into 2026, we are positioning to advance multiple high-value clinical programs, expand our RADR ® platform’ s commercial reach and revenue potential globally through our new AI Center of Excellence in India and strengthen our balance sheet.”. On average, our newly developed drug programs have been advanced from initial AI insights to...

#LTRN Lantern Pharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

www.stocktitan.net/news/LTRN/lantern-pharma...

Lantern Pharma Confirms Panna Sharma Continues to Serve as President and CEO; Alerts Investors to False Third-Party Report Lantern Pharma (NASDAQ: LTRN) confirmed that Panna Sharma remains President, CEO, and director after a false third‑party article claimed he stepped down. The board affirmed confidence, cited a recently cleared IND for STAR-001 pediatric CNS trial, and warned of potential market manipulation while investigating and considering legal and regulatory referrals.The company reiterated reliance on official SEC filings and its investor site and noted a webcast on March 30, 2026 at 4:30 p.m. ET to review FY2025 results.

#LTRN Lantern Pharma Confirms Panna Sharma Continues to Serve as President and CEO; Alerts Investors to False Third-Party Report

www.stocktitan.net/news/LTRN/lantern-pharma...

Lantern Pharma and Starlight Therapeutics Announce FDA Clearance of IND for a Planned Phase 1 Pediatric CNS Cancer Trial of STAR-001 Lantern Pharma (NASDAQ: LTRN) and Starlight Therapeutics announced FDA clearance of IND No. 179145 to initiate a planned Phase 1 pediatric CNS trial of STAR-001 (LP-184). The multicenter study will test STAR-001 as monotherapy and with spironolactone across relapsed/refractory ATRT, DIPG, GBM, medulloblastoma, and ependymoma, enrolling ~18–42 patients at POETIC sites. Preclinical data showed ERCC3 protein reduction ≥50% and a combination survival benefit (median 27 to 76 days, +181%, p=0.0018). Trial initiation is subject to additional funding.

#LTRN Lantern Pharma and Starlight Therapeutics Announce FDA Clearance of IND for a Planned Phase 1 Pediatric CNS Cancer Trial of STAR-001

www.stocktitan.net/news/LTRN/lantern-pharma...

Lantern Pharma's LP-284 Receives FDA Orphan Drug Designation for Soft Tissue Sarcomas Lantern Pharma (NASDAQ: LTRN) announced that the FDA granted Orphan Drug Designation to LP-284 for the treatment of soft tissue sarcomas on January 20, 2026. The designation is Lantern’s third for LP-284 and sixth overall for its pipeline, and could provide 7 years of U.S. market exclusivity if approved plus tax credits and user-fee exemptions. LP-284 targets DNA repair deficiencies via a synthetic lethal TC-NER mechanism. Lantern cites ~96,200 global annual soft tissue sarcoma cases and a seven‑market therapeutic value of ~$2.4 billion in 2025 (projected to ~$4.7 billion by 2035). LP-284 remains in a Phase 1 trial (NCT06132503) with early single-patient clinical activity reported.

#LTRN Lantern Pharma's LP-284 Receives FDA Orphan Drug Designation for Soft Tissue Sarcomas

www.stocktitan.net/news/LTRN/lantern-pharma...

Lantern Pharma Reports Third Quarter 2025 Financial Results and Provides Business Updates Lantern Pharma (NASDAQ: LTRN) reported Q3 2025 results and clinical progress on November 13, 2025. Key clinical milestones include LP-184 Phase 1a achieving all primary endpoints with a 48% clinical benefit rate at/above the therapeutic dose and an RP2D of 0.39 mg/kg. FDA Type C meeting provided regulatory guidance for a pediatric ATRT program and confirmed a spironolactone combination strategy. LP-300 Phase 2 HARMONIC™ enrollment and LP-284 data presentation advanced partnership discussions. RADR® AI modules demonstrated commercial readiness. Financials: cash and equivalents ~$12.4M as of Sept 30, 2025, providing runway into ~Q3 2026. Webcast scheduled Nov 13, 2025.

#LTRN Lantern Pharma Reports Third Quarter 2025 Financial Results and Provides Business Updates

www.stocktitan.net/news/LTRN/lantern-pharma...

Breakthrough for Rare Childhood Brain Cancer: Lantern Pharma's AI-Driven Drug Gets FDA Trial Guidance Biotech firm receives FDA feedback for LP-184/STAR-001 trial in ATRT and CNS cancers. Plans include spironolactone combination therapy and multi-site study launching Q1 2026.

#LTRN Lantern Pharma Announces Completion of Type C Meeting with FDA, Providing Clarity on Regulatory Pathway for Pediatric CNS Cancer Trial

www.stocktitan.net/news/LTRN/lantern-pharma...

Lantern Pharma Reports Second Quarter 2025 Financial Results and Business Updates Lantern Pharma (NASDAQ:LTRN) reported significant Q2 2025 achievements across its clinical pipeline and AI platform development. The company achieved major milestones including: successful completion of LP-184 Phase 1a enrollment with 65 patients, a remarkable complete response in the HARMONIC™ Trial for LP-300, and a complete metabolic response in an LP-284 trial patient.Financial highlights include $15.9 million in cash and equivalents as of June 30, 2025, providing runway into June 2026. Q2 net loss was $4.33 million ($0.40 per share), improved from $4.96 million in Q2 2024. The company launched PredictBBB.ai™, an AI module for blood-brain barrier penetrability prediction, and enhanced its RADR® platform with new drug combination prediction capabilities.

#LTRN Lantern Pharma Reports Second Quarter 2025 Financial Results and Business Updates

www.stocktitan.net/news/LTRN/lantern-pharma...

Lantern Pharma Announces Public Release of Transformative, Advanced AI Module for Blood-Brain Barrier Permeability Prediction, predictBBB.ai™ Lantern Pharma (NASDAQ:LTRN) has publicly released predictBBB.ai™, a groundbreaking AI module for predicting blood-brain barrier (BBB) permeability with 94% accuracy, 95% sensitivity, and 89% specificity. The platform leverages billions of data points across millions of compounds to address a critical pharmaceutical challenge, as only 2-6% of small-molecule drugs successfully cross the blood-brain barrier.The technology currently holds five of the top eleven positions on the Therapeutic Data Commons Leaderboard. The BBB technologies market is projected to grow from $1.4 billion in 2023 to $9.85 billion by 2032. Lantern is implementing a freemium business model to accelerate adoption while creating pathways for strategic collaborations across the pharmaceutical ecosystem.

#LTRN Lantern Pharma Announces Public Release of Transformative, Advanced AI Module for Blood-Brain Barrier Permeability Prediction, predictBBB.ai™

www.stocktitan.net/news/LTRN/lantern-pharma...

Breakthrough Lung Cancer Drug Shows 86% Success Rate in Never-Smokers, Japan Trial Fully Enrolled LP-300 trial targets $4B never-smoker lung cancer market with 86% clinical benefit rate. Early data shows complete response in some patients. See latest results.

#LTRN Lantern Pharma Completes Targeted Enrollment for Lung Cancer Phase 2 Harmonic™ Clinical Trial in Japan for LP-300

www.stocktitan.net/news/LTRN/lantern-pharma...

Lantern Pharma Reports Complete Response in Heavily Pre-Treated Lymphoma Patient with LP-284 in Phase 1 Clinical Trial Lantern Pharma (NASDAQ:LTRN) has reported a groundbreaking complete metabolic response in a heavily pre-treated lymphoma patient using LP-284 in its Phase 1 clinical trial. The 41-year-old patient, who had previously failed three aggressive treatment regimens including R-CHOP chemotherapy, CAR-T therapy, and bispecific antibody therapy, achieved complete response after just two 28-day cycles of LP-284.The AI-guided drug development, powered by Lantern's RADR® platform, enabled the company to advance LP-284 from concept to clinical milestone in under three years at approximately $3 million. This success positions LP-284 to potentially address a critical need in the $4 billion global blood cancer market, particularly for DLBCL, which affects approximately 200,000 patients globally each year.

#LTRN Lantern Pharma Reports Complete Response in Heavily Pre-Treated Lymphoma Patient with LP-284 in Phase 1 Clinical Trial

www.stocktitan.net/news/LTRN/lantern-pharma...

Lantern Pharma Secures EU Patent Allowance for LP-284, Bolstering Global IP Position for AI-Developed Cancer Therapy Lantern Pharma (NASDAQ:LTRN) has received a notice of allowance from the European Patent Office for LP-284, its AI-developed cancer therapy. The patent, extending through early 2039, covers the composition of matter for LP-284, which targets B-cell lymphomas and other B-cell malignancies.LP-284, developed using Lantern's RADR® AI platform, is currently in Phase 1 clinical trials with potential completion in late 2025. The drug has received Orphan Drug Designations from the FDA for both mantle cell lymphoma (MCL) and high-grade B-cell lymphomas (HGBL). The therapy addresses a $4 billion annual market for blood cancers.The development of LP-284 was notably efficient, achieving clinical trial readiness in under three years at a cost of $1.5 to $2.0 million. The patent complements existing protections in the US, Japan, India, and Mexico, with pending applications in other key markets.

#LTRN Lantern Pharma Secures EU Patent Allowance for LP-284, Bolstering Global IP Position for AI-Developed Cancer Therapy

www.stocktitan.net/news/LTRN/lantern-pharma...

Lantern Pharma Unveils Groundbreaking AI-Powered Module to Predict Activity and Efficacy of Combination Regimens in Clinical Cancer Treatment Lantern Pharma (NASDAQ:LTRN) has launched an innovative AI-powered module within its RADR® platform to predict the effectiveness of combination cancer treatments. The module, trained on 221 clinical trials, focuses on DNA damaging agents (DDAs) and DNA repair inhibitors (DDRis), targeting a $50+ billion market growing at 8.5% annually through 2030.The AI system has already demonstrated success by guiding an FDA-cleared Phase 1B/2 trial design combining LP-184 with olaparib for triple-negative breast cancer. The platform analyzes genomic, transcriptomic, and clinical data to predict drug synergies and identify optimal patient populations, potentially reducing development timelines and costs by one-third compared to traditional methods.Key findings include an 80% positive outcome rate in non-PARP DDRi combinations, particularly with WEE1 inhibitors and platinum agents in TP53-mutated cancers.

#LTRN Lantern Pharma Unveils Groundbreaking AI-Powered Module to Predict Activity and Efficacy of Combination Regimens in Clinical Cancer Treatment

www.stocktitan.net/news/LTRN/lantern-pharma...

Breakthrough: Advanced Lung Cancer Patient Achieves Complete Response After 3 Failed Therapies Advanced lung cancer patient shows complete response in HARMONIC trial after failing Keytruda and other treatments. See unprecedented 2-year survival data.

#LTRN Lung Cancer Patient in Lantern Pharma’s Harmonic Trial Shows Durable Complete Response in Target Cancer Lesions with Survival Continuing for Nearly Two Years

www.stocktitan.net/news/LTRN/lung-cancer-pa...

Lantern Pharma Inc. (NASDAQ:LTRN) Focuses on Precision Oncology Therapies with AI

#stockMarket #investing Lantern Pharma Inc. (NASDAQ: #LTRN) Focuses on Precision Oncology Therapies with AI www.stocks2buynow.com/newsitems/la... 📈📉

#LTRN: First Quarter 2025 Financial Results buff.ly/tnXBNaL

PRISM Mid-Day Movers:
#TSS, Inc. ( #TSSI) rocketed 77%
#AcadiaPharma Inc. ( #ACAD) climbed 35%,
Other PRISM Mid-Day Movers:
( #AENT): +14.34%
( #EVLV): +19.05%
( #TNXP): +18.01%
( #LTRN): -19.69%
Read more: prismmarketview.com/prism-mid-da...

Lantern Pharma Reports First Quarter 2025 Financial Results and Business Updates Lantern Pharma (NASDAQ: LTRN) reported Q1 2025 financial results and key developments. The company is nearing completion of LP-184 Phase 1a trial enrollment with 62-65 patients by June 2025. Their LP-300 HARMONIC Trial in never-smoker NSCLC patients showed promising preliminary results with 86% clinical benefit rate and 43% objective response rate. The company's RADR® AI platform expanded to 200 billion oncology-focused data points, with new modules for ADC development. Financial position remains stable with $19.7 million in cash and equivalents as of March 31, 2025, providing runway through May 2026. Q1 2025 showed reduced net loss of $4.5 million ($0.42/share) compared to $5.4 million ($0.51/share) in Q1 2024. R&D expenses decreased to $3.3 million from $4.3 million year-over-year, while G&A expenses remained stable at $1.5 million.

#LTRN Lantern Pharma Reports First Quarter 2025 Financial Results and Business Updates

www.stocktitan.net/news/LTRN/lantern-pharma...

Lantern Pharma Secures FDA Clearance for Planned Phase 1b/2 Trial of LP-184 in Biomarker-Defined, Treatment-Resistant NSCLC Patients with High Unmet Clinical Need Lantern Pharma (NASDAQ: LTRN) has received FDA clearance for its IND application amendment to begin a Phase 1b/2 clinical trial of LP-184 in non-small cell lung cancer (NSCLC). The trial will evaluate LP-184 in combination with immune checkpoint inhibitors (nivolumab and ipilimumab) in patients with KEAP1 and/or STK11 mutations and low PD-L1 expression. LP-184, developed using Lantern's AI platform RADR®, is a synthetically lethal small molecule that shows promise in treating this specific patient population, which currently has limited treatment options and a median survival of just 15 months. The targeted market opportunity exceeds $2 billion annually. Preclinical studies show LP-184's effectiveness correlates with PTGR1 expression levels, which are elevated in about 35% of lung cancer patients, particularly those with KEAP1 mutations.

#LTRN Lantern Pharma Secures FDA Clearance for Planned Phase 1b/2 Trial of LP-184 in Biomarker-Defined, Treatment-Resistant NSCLC Patients with High Unmet Clinical Need

www.stocktitan.net/news/LTRN/lantern-pharma...

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with strong volume gains, Wed May 7th - #ZKIN #SKIN #RITR #PRCH #NRDS #LTRN #KE #IVVD #EOSE #EHTH #XGN #TROO #CHR #ATOM #OSCR #TPB #TIC #IHS #FTK #BALY - More: crystalequityresearch.com/SmCpStr/ - #smallcap

#LTRN: IND Clearance for LP-184 in TNBC buff.ly/CGL2NFx

Lantern Advances Drug Candidate LP-184 with IND Clearance for Phase 1b/2 Clinical Trial in Triple Negative Breast Cancer (TNBC) Lantern Pharma (LTRN) has received FDA clearance for its IND application to begin a Phase 1b/2 clinical trial of LP-184 in Triple Negative Breast Cancer (TNBC). The trial will evaluate LP-184 through two approaches: a monotherapy arm with approximately 30 advanced-stage TNBC patients, and a combination therapy with olaparib for second-line TNBC patients with BRCA1/2 alterations. LP-184, developed using Lantern's AI platform RADR®, is a novel small molecule that targets DNA damage in cancer cells. The drug previously received FDA Orphan Drug Designation (2023) and Fast Track Designation (2024) for TNBC treatment. The trials will be conducted in the US, India, and Nigeria, targeting regions with high TNBC incidence. The global TNBC market opportunity exceeds $4 billion annually, with over 300,000 new cases diagnosed worldwide each year.

#LTRN Lantern Advances Drug Candidate LP-184 with IND Clearance for Phase 1b/2 Clinical Trial in Triple Negative Breast Cancer (TNBC)

www.stocktitan.net/news/LTRN/lantern-advanc...

LTRN: 2024 Financial Results By John Vandermosten, CFA MKT:TICKER READ THE FULL LTRN RESEARCH REPORT Lantern Pharma, Inc (NASDAQ:LTRN) reports 2024 results highlighting several achievements including progress on its HARMONIC, LP-184 and LP-284 trials, a portfolio of expedited designations in multiple indications and advances in the RADR platform with modules that offer predictive algorithms for blood brain barrier (BBB)

#LTRN: 2024 Financial Results buff.ly/i78sNko

Breakthrough: Lantern's Cancer Drug Shows 86% Success Rate in Lung Cancer Trial, Latest Earnings Reveal Major AI Advances HARMONIC trial demonstrates 86% clinical benefit in lung cancer patients. Multiple FDA Fast Track designations secured as AI platform reaches 100B data point milestone.

#LTRN #ACTU Lantern Pharma Provides Business Updates and Fourth Quarter & Year-End 2024 Financial Results

www.stocktitan.net/news/LTRN/lantern-pharma...

#LTRN: M&A Illuminates GBM Value buff.ly/mpaoqsJ

Lantern Pharma's AI Platform Breakthrough: 82 New ADC Targets Could Slash Development Time 50% Revolutionary AI platform identifies promising cancer drug targets and could reduce ADC development costs by 60%. Platform validates 729 potential payloads in growing $30.4B market.

#LTRN Lantern Pharma Unveils Innovative AI-Powered Module to Improve the Precision, Cost and Timelines of Antibody-Drug Conjugate (ADC) Development for Cancer

www.stocktitan.net/news/LTRN/lantern-pharma...

JUST IN: ( NASDAQ: #LTRN ) Lantern Pharma Inc. (NASDAQ: LTRN) Highlighted for Surprising Price Action

Lantern Pharma's Lung Cancer Drug Shows 86% Benefit Rate as Phase 2 Trial Expands to Taiwan LP-300 demonstrates promising early results for never-smoker lung cancer patients. Phase 2 trial now enrolling in Taiwan, where 50% of lung cancer affects never-smokers.

#LTRN Lantern Pharma Announces First Patient Enrolled in Taiwan for Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients

#clinicaltrial #investing #stocks

www.stocktitan.net/news/LTRN/lantern-pharma...

NEWS: ( NASDAQ: #LTRN ) Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Second Fast Track Designation from FDA for Treatment of Triple Negative Breast Cancer (TNBC)

#StockMarket #News

#LTRN Lantern Pharma Announces First Patient Dosed in Japan for The Expansion Cohort in The Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients

www.stocktitan.net/news/LTRN/lantern-pharma...

JUST IN: ( NASDAQ: #LTRN ) Lantern Pharma Highlights Promising Preclinical Results of LP-184's Synergy with Checkpoint Inhibitors & Sensitizing Tumors That are Non-Responsive to Anti-PD1 Therapy in Collaboration with MD Anderson at Immuno-Oncology Summit 2024

#StockMarket #News